Here, we provide evidence that human TIMP3 overexpression in myeloid lineage, conditional deletion of ADAM17 in podocytes, and intervention with innovative kidney‐targeted TIMP3 derived peptides, result in protection from renal damage in experimental models of DN. This evidence concerns the gene ADAM17 and liver dysplastic nodule.